Study guide

14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment

CAMC Regional Medical Registration Examination Part 1 MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Registration Framework & Test Strategy

1.1 Exam Format, Administration & Caribbean Medical Registration Pathways 1.2 Clinical Reasoning & Single-Best-Answer MCQ Test-Taking Strategy 1.3 Regional Epidemiology & Caribbean Healthcare Context

2 Chapter 2: Internal Medicine: Cardiovascular Disorders

2.1 Acute Coronary Syndromes & Myocardial Infarction Management 2.2 Heart Failure Syndromes & Cardiogenic Shock 2.3 Cardiac Arrhythmias, Conduction Blocks & BLS/ACLS Algorithms 2.4 Valvular Heart Disease, Infective Endocarditis & Hypertension

3 Chapter 3: Internal Medicine: Respiratory Medicine & Critical Care

3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations 3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis 3.3 Pulmonary Embolism, Pleural Effusion & Pneumothorax

4 Chapter 4: Internal Medicine: Endocrinology & Metabolic Disorders

4.1 Diabetes Mellitus, Diabetic Ketoacidosis & Hyperosmolar Hyperglycaemic State 4.2 Thyroid Disorders: Thyrotoxicosis, Hypothyroidism & Thyroid Storm 4.3 Adrenal Disorders, Pituitary Pathology & Calcium Homeostasis

5 Chapter 5: Internal Medicine: Gastroenterology, Hepatology & Nephrology

5.1 Upper & Lower Gastrointestinal Bleeding: Evaluation & Management 5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy 5.3 Acute Kidney Injury & Chronic Kidney Disease Staging 5.4 Fluid, Electrolyte & Acid-Base Emergencies

6 Chapter 6: Internal Medicine: Neurology, Haematology & Infectious Diseases

6.1 Stroke, Transient Ischaemic Attack & Acute Neurological Deficits 6.2 Sickle Cell Disease, Haemoglobinopathies & Transfusion Medicine 6.3 Dengue Fever, Arboviral Infections & Leptospirosis 6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship

7 Chapter 7: General Surgery: Acute Abdomen & Surgical Emergencies

7.1 Acute Abdomen: Peritonitis, Appendicitis & Acute Cholecystitis 7.2 Intestinal Obstruction, Bowel Ischaemia & Perforated Viscus 7.3 Abdominal Wall Hernias: Inguinal, Femoral, Umbilical & Strangulation 7.4 Upper & Lower GI Surgical Pathology & Postoperative Complications

8 Chapter 8: General Surgery: Trauma Resuscitation, Shock & Critical Care

8.1 ATLS Primary Survey & Hemorrhagic Shock Resuscitation 8.2 Thoracic Trauma: Tension Pneumothorax, Hemothorax & Flail Chest 8.3 Abdominal & Pelvic Trauma: FAST Examination & Damage Control Surgery 8.4 Traumatic Brain Injury, Burns & Wound Management

9 Chapter 9: General Surgery: Surgical Subspecialties & Perioperative Care

9.1 Urological Emergencies: Acute Retention, Renal Colic, Torsion & Hematuria 9.2 Musculoskeletal Trauma: Fractures, Dislocations & Compartment Syndrome 9.3 Preoperative Assessment, Surgical Site Infections & Fluid Management 9.4 Otolaryngology: Ear, Nose, Throat & Upper Airway Emergencies 9.5 Clinical Ophthalmology: Acute Red Eye, Glaucoma & Retinal Emergencies

10 Chapter 10: Obstetrics: Antenatal Care, Labor & Complications

10.1 Routine Antenatal Care, Screening & Fetal Assessment 10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia 10.3 Antepartum Haemorrhage: Placenta Praevia & Placental Abruption 10.4 Normal Labor, Labor Dystocia & Obstetric Analgesia

11 Chapter 11: Obstetrics & Gynaecology: Postpartum & Pathology

11.1 Postpartum Haemorrhage, Normal Puerperium Physiology & Postpartum Care 11.2 Ectopic Pregnancy, Miscarriage & Gestational Trophoblastic Disease 11.3 Abnormal Uterine Bleeding & Pelvic Inflammatory Disease 11.4 Contraception, Cervical Cancer Screening & Gynaecological Malignancies 11.5 Obstetric & Gynaecological Instruments & Cervical Specimen Collection (PAP Smear Procedures)

12 Chapter 12: Paediatric Medicine: Neonatal Care, Growth & Nutrition

12.1 Neonatal Resuscitation, APGAR Scoring & Prematurity Complications 12.2 Neonatal Jaundice: Physiological, Pathological & Kernicterus 12.3 Growth Monitoring, Developmental Milestones & Failure to Thrive 12.4 Protein-Energy Malnutrition: Kwashiorkor, Marasmus & Nutritional Deficiencies

13 Chapter 13: Paediatric Medicine: Common Illnesses & Emergencies

13.1 Acute Gastroenteritis, Dehydration Assessment & WHO ORS Protocols 13.2 Paediatric Respiratory Illness: Croup, Bronchiolitis & Asthma 13.3 Childhood Infections, Exanthems & Caribbean Immunisation Schedules 13.4 Paediatric Surgical & Medical Emergencies: Intussusception & Febrile Seizures 13.5 Social Paediatrics, Child Protection & Vulnerable Child Health

14 Chapter 14: Psychiatry: Clinical Assessment & Psychopharmacology

14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment 14.2 Psychosis, Schizophrenia & Acute Delirium vs Dementia 14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects

15 Chapter 15: Community Health, Epidemiology & Preventive Medicine

15.1 Epidemiological Study Designs, Measures of Association & Bias 15.2 Screening Test Performance: Sensitivity, Specificity, PPV & NPV 15.3 Outbreak Investigation, Levels of Prevention & Caribbean NCD Control

16 Chapter 16: Internal Medicine: Rheumatology, Connective Tissue & Dermatology

16.1 Connective Tissue & Collagen Vascular Diseases 16.2 Bone & Joint Diseases: Non-Traumatic Arthropathies & Metabolic Bone Disorders 16.3 Clinical Dermatology: Common, Inflammatory, Bullous, Malignant & Drug-Induced Dermatoses

17 Chapter 17: Anaesthetics, Intensive Care & Clinical Measurements

17.1 Important Anaesthetic Techniques, Airway Management & Methods of Administration 17.2 Clinical Measurements & Intensive Care Monitoring: Cardiac Output, Arterial Blood Gases & Pulmonary Functions 17.3 Acute Pain Management, Multimodal Analgesia & Critical Care Sedation

14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment

Key Takeaways Explain This Topic AI

Major Depressive Disorder (MDD) requires at least 5 of 9 SIGECAPS symptoms present for at least 2 weeks, with mandatory inclusion of depressed mood or pervasive anhedonia, after systematically excluding medical mimics such as hypothyroidism, anemia, and corticosteroid-induced mood changes.

First-line pharmacotherapy for MDD utilizes SSRIs (such as sertraline or escitalopram), which require 2 to 4 weeks for therapeutic clinical onset; tricyclic antidepressants (TCAs) carry severe overdose fatality due to myocardial fast sodium channel blockade, producing QRS widening and fatal ventricular dysrhythmias treatable with IV sodium bicarbonate.

Bipolar I disorder is defined by at least one lifetime manic episode lasting at least 7 days (or requiring hospitalization) exhibiting DIG FAST symptoms, whereas Bipolar II requires hypomanic episodes (at least 4 days without psychosis or marked functional impairment) and major depressive episodes; avoid antidepressant monotherapy in bipolar I or mixed states because of manic-switch risk; selected nonmixed bipolar II depression requires specialist treatment advice.

Lithium remains a foundational mood stabilizer with a narrow therapeutic index (0.6 to 1.0 mmol/L for maintenance, 0.8 to 1.2 mmol/L for acute mania); severe toxicity (> 1.5 to 2.0 mmol/L) produces coarse tremor, ataxia, hyperreflexia, and seizures, with urgent dialysis assessment for major neurotoxicity/dysrhythmias at any level or lithium >4.0 mmol/L with impaired renal function; EXTRIP suggests additional indications.

Suicide risk evaluation necessitates direct, empathetic inquiry into suicidal ideation, intent, plan, and lethal means access; in the Caribbean region, lethal means restriction prominently targets agricultural organophosphate and paraquat poisons, and immediate danger requires urgent psychiatric assessment, observation and lawful protective action using the jurisdiction's compulsory-care criteria and safeguards.

Last updated: November 2026

Diagnostic Classification & Clinical Evaluation of Major Depressive Disorder

Major Depressive Disorder (MDD) represents a leading cause of functional disability worldwide and across the Caribbean healthcare landscape. Accurate recognition demands a rigorous clinical interview that differentiates unipolar depression from normal bereavement, adjustment disorders, bipolar affective illness, and organic medical conditions mimicking mood disorders.

DSM-5 Diagnostic Criteria & The SIGECAPS Framework

According to the DSM-5, a diagnosis of Major Depressive Disorder requires the presence of at least 5 of the following 9 symptoms during the same 2-week period , representing a clear departure from previous functioning. At least one of the symptoms must be either depressed mood or loss of interest or pleasure (anhedonia) :

S – Sleep Disturbances: Insomnia (characteristically terminal insomnia with early morning awakening 2 to 3 hours prior to the alarm) or hypersomnia.

I – Interest Deficit (Anhedonia): Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day.

G – Guilt & Worthlessness: Excessive, inappropriate, or delusional feelings of worthlessness or guilt (not merely self-reproach about being sick).

E – Energy Deficit: Pervasive fatigue, loss of stamina, or severe anergia nearly every day.

C – Concentration Impairment: Diminished ability to think, concentrate, or make minor decisions, often reported by family members as cognitive slowing (pseudodementia in the elderly).

A – Appetite & Weight Alterations: Significant weight loss when not dieting or weight gain (a change of more than 5% of body weight in a month), or decrease/increase in appetite nearly every day.

P – Psychomotor Alterations: Psychomotor agitation (pacing, hand-wringing, inability to sit still) or retardation (slowed speech, increased response latency, poverty of movement) observable by others.

S – Suicidal Ideation: Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or specific plan for committing suicide.

Diagnostic Requirements: Symptoms must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning, and must not be attributable to the direct physiological effects of a substance or general medical condition, nor better explained by a schizoaffective spectrum disorder.

Systematic Exclusion of Organic & Medical Mimics

Before initiating psychotropic therapy, the clinician must systematically exclude reversible biological etiologies through targeted diagnostic testing:

Endocrine Pathologies: Primary hypothyroidism is the most frequent medical mimic; obtain serum Thyroid-Stimulating Hormone (TSH) and Free T4. Additional endocrine triggers include Cushing's syndrome (hypercortisolemia), Addison's disease (adrenal insufficiency), and primary hyperparathyroidism (hypercalcemia presenting with fatigue, constipation, and depression).

Hematologic & Nutritional Deficiencies: Severe iron deficiency anemia and vitamin B12 (cobalamin) or folate deficiency induce profound fatigue, cognitive blunting, and depressive affect. Use a full blood count, ferritin, B12/folate levels and blood film when the history, examination or initial results suggest anaemia or nutritional deficiency .

Cerebrovascular & Neurological Disorders: Post-stroke depression occurs in up to 30% to 50% of patients following ischemic or hemorrhagic stroke, especially with left frontal cortical and basal ganglia lesions. Early-stage Parkinson's disease, multiple sclerosis, and normal pressure hydrocephalus also frequently present with prominent mood changes.

Chronic Infectious Diseases: HIV-associated neurocognitive and depressive disorders, chronic hepatitis C, and neurosyphilis (obtain VDRL/RPR) should be actively investigated in regional clinical practice.

Medication-Induced Depressive Disorders: Systemic corticosteroids (prednisone, dexamethasone), interferon-alpha, centrally acting antihypertensives (methyldopa, reserpine, propranolol), oral contraceptive agents, and withdrawal from psychostimulants (cocaine, amphetamines) or chronic alcohol misuse.

Pharmacotherapy of Depressive Disorders

Modern antidepressant selection is governed by side effect tolerability, safety in overdose, comorbid medical conditions, and previous individual or familial drug responses.

1. Selective Serotonin Reuptake Inhibitors (SSRIs)

First-Line Agents: Sertraline, escitalopram, citalopram, and fluoxetine.

Mechanism of Action: Selectively block the presynaptic serotonin reuptake transporter (SERT / SLC6A4), increasing synaptic serotonin (5-HT) availability and subsequently downregulating inhibitory 5-HT1A somatodendritic autoreceptors over time.

Clinical Pharmacokinetics & Onset: Antidepressant efficacy exhibits a characteristic therapeutic lag of 2 to 4 weeks (and up to 6 to 8 weeks for full clinical response). Patients must be educated that physical vegetative symptoms (sleep, energy, appetite) generally improve before mood and suicidal ideation lift.

Adverse Effects: Early transient gastrointestinal upset (nausea, diarrhea due to 5-HT3 stimulation), tension headache, and paradoxical agitation/anxiety; long-term sexual dysfunction (delayed ejaculation, anorgasmia, decreased libido in 30% to 50% of patients); hyponatremia secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), particularly in elderly patients on diuretics.

Discontinuation Syndrome: Abrupt cessation of SSRIs with short half-lives (e.g., paroxetine, sertraline) triggers dizziness, electric shock-like sensations (brain zaps), paresthesias, insomnia, and flu-like symptoms. Fluoxetine has an active metabolite (norfluoxetine) with an elimination half-life of 7 to 15 days, self-tapering and conferring the lowest risk of withdrawal.

2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Agents: Venlafaxine, duloxetine, desvenlafaxine.

Mechanism: Dual inhibition of SERT and the norepinephrine transporter (NET). Duloxetine exhibits balanced SERT and NET inhibition across therapeutic doses; venlafaxine blocks SERT at low doses (< 150 mg/day) and NET at higher doses (>= 150-225 mg/day).

Clinical Utility: First-line alternative for major depression, especially when complicated by comorbid chronic neuropathic pain, diabetic peripheral neuropathy, or fibromyalgia.

Key Adverse Effects: Noradrenergic stimulation can cause dose-dependent sustained hypertension (mandatory blood pressure monitoring), tachycardia, diaphoresis, and dry mouth.

3. Tricyclic Antidepressants (TCAs)

Agents: Amitriptyline, imipramine, nortriptyline, clomipramine.

Mechanism: Block SERT and NET, but also act as potent competitive antagonists at muscarinic acetylcholine (M1), histamine (H1), and alpha-1 adrenergic receptors.

Adverse Profile: Anticholinergic toxicity (dry mouth, blurred vision, urinary retention, severe constipation, precipitation of acute angle-closure glaucoma, delirium in the elderly); antihistaminic sedation and weight gain; alpha-1 blockade causing orthostatic hypotension and reflex tachycardia.

Lethality in Overdose: TCAs possess a notoriously narrow therapeutic index. Ingestion of as little as 10 to 20 mg/kg can be fatal. TCAs block myocardial fast inward voltage-gated sodium channels (phase 0 depolarization), prolonging the QRS duration (> 100 ms predicts seizures; > 160 ms predicts life-threatening ventricular arrhythmias, including ventricular tachycardia, ventricular fibrillation, and torsades de pointes).

TCA Overdose Management: Secure airway and establish continuous ECG monitoring. The specific antidote is Intravenous Sodium Bicarbonate (1 to 2 mmol/kg IV bolus, repeated to maintain blood arterial pH between 7.45 and 7.55 and narrow the QRS complex below 100 ms) . Alkalinization decreases the fraction of free active ionized drug, and the high extracellular sodium load overcomes competitive sodium channel blockade.

4. Monoamine Oxidase Inhibitors (MAOIs)

Agents: Phenelzine, tranylcypromine, isocarboxazid, moclobemide (reversible MAO-A inhibitor).

Mechanism: Phenelzine, tranylcypromine and isocarboxazid irreversibly inhibit MAO-A and MAO-B; moclobemide reversibly inhibits MAO-A . These actions reduce monoamine breakdown.

The Tyramine "Cheese Reaction": Ingestion of foods rich in tyramine (aged cheeses, cured meats, red wine, draft beer, fava beans, marmite, soy sauce) precipitates a life-threatening hypertensive crisis . Dietary tyramine is normally metabolized by gastrointestinal and hepatic MAO-A; with MAOI inhibition, unmetabolized tyramine enters the systemic circulation, is taken up into presynaptic adrenergic terminals via NET, and displaces massive quantities of vesicular norepinephrine into the synaptic cleft.

Washout Period: Switch under specialist guidance: allow at least 14 days after an irreversible MAOI before most other antidepressants, but moclobemide usually requires 24 hours before an SSRI/SNRI. The interval before starting an MAOI depends on the stopped drug; after fluoxetine, wait 5–6 weeks to prevent serotonin toxicity.

Bipolar Affective Disorders: Diagnostic Divergence & Mood Stabilizers

Bipolar affective disorder is a chronic, relapsing condition characterized by pathological oscillations in mood, energy, and activity levels. Accurate differentiation between unipolar depression and bipolar depression is critical because antidepressant monotherapy in bipolar patients risks triggering manic induction, rapid cycling, and clinical instability.

Diagnostic Divergence: Bipolar I vs. Bipolar II vs. Cyclothymia

Bipolar I Disorder: Defined by the occurrence of at least one lifetime manic episode . Major depressive episodes and hypomanic episodes are common throughout the disease course but are not strictly required for DSM-5 diagnosis. A manic episode requires an abnormally and persistently elevated, expansive, or irritable mood and abnormally increased goal-directed activity or energy, lasting at least 1 week (or any duration if hospitalization is necessary), present most of the day, nearly every day.

Diagnostic Mnemonic for Mania – DIG FAST:

D – Distractibility: Attention too easily drawn to unimportant or irrelevant external stimuli.

I – Indiscretion / Impulsivity: Excessive involvement in activities with high potential for painful consequences (unrestrained buying sprees, sexual indiscretions, foolish business investments).

G – Grandiosity: Inflated self-esteem or grandiose beliefs (special powers, divine missions, unchallengeable authority).

F – Flight of Ideas: Subjective experience that thoughts are racing, accompanied by rapid shifts in topics.

A – Activity Increase: Marked increase in goal-directed activity (socially, at work, or sexually) or psychomotor agitation.

S – Sleep Deficit: Decreased need for sleep (e.g., feels rested after only 2 or 3 hours of sleep; distinct from insomnia where the patient desires sleep but cannot achieve it).

T – Talkativeness (Pressured Speech): Speech is rapid, loud, continuous, and difficult to interrupt.

Bipolar II Disorder: Characterized by a lifetime clinical course of at least one hypomanic episode AND at least one major depressive episode . A hypomanic episode lasts at least 4 consecutive days with DIG FAST symptoms, represents an unequivocal change in functioning, but is NOT severe enough to cause marked impairment in social or occupational functioning, does NOT require hospitalization, and NEVER features psychotic symptoms. If psychosis or hospitalization occurs, the episode is categorized as mania, establishing a diagnosis of Bipolar I.

Cyclothymic Disorder: For at least 2 years (1 year in children/adolescents), numerous periods with hypomanic symptoms that do not meet full hypomania criteria and depressive symptoms that do not meet full major depressive episode criteria.

Comparative Pharmacodynamics of Mood Stabilizers

Agent Primary Mechanism of Action Therapeutic Serum Target Key Adverse Effects Mandatory Clinical Monitoring

Lithium Inhibits inositol monophosphatase (IMPase) and glycogen synthase kinase-3 (GSK-3); modulates adenylate cyclase Acute Mania: 0.8 - 1.2 mmol/L ; Maintenance: 0.6 - 1.0 mmol/L Nephrogenic diabetes insipidus, hypothyroidism, hyperparathyroidism, fine resting tremor, weight gain, cardiac conduction blunting Baseline and 6-monthly: Serum creatinine/eGFR, TSH, electrolytes, calcium. 12-hour post-dose trough lithium level

Sodium Valproate Increases brain GABA concentrations; blocks voltage-gated Na+ channels and T-type Ca2+ channels Acute Bipolar Mania: 50 - 100 mcg/mL (350 - 700 umol/L) Hepatotoxicity, acute pancreatitis, thrombocytopenia, weight gain, alopecia, hyperammonemia, polycystic ovarian syndrome Baseline and serial LFTs, complete blood count (platelets), coagulation profile, serum ammonia if lethargic

Carbamazepine Potent voltage-gated sodium channel blocker; reduces glutamate release Anticonvulsant / Mood range: 4 - 12 mcg/mL CYP3A4 autoinduction, aplastic anemia, agranulocytosis, hyponatremia (SIADH), Stevens-Johnson syndrome Baseline CBC, LFTs, electrolytes; screen for HLA-B*1502 allele in susceptible Asian/Caribbean ancestries

Atypical Antipsychotics Quetiapine/olanzapine: D2 and 5-HT2A antagonism; aripiprazole: D2/5-HT1A partial agonism and 5-HT2A antagonism Clinical titration Metabolic syndrome (weight gain, dyslipidemia, insulin resistance), sedation, mild extrapyramidal symptoms Baseline weight/BMI, BP, glucose or HbA1c and lipids; weight weekly for 6 weeks, then at 12 weeks; glucose/HbA1c and lipids at 12 weeks, then at least annually

Clinical Management of Lithium Toxicity

Lithium has an exceptionally narrow therapeutic window. Serum levels must be drawn precisely 12 hours after the evening dose.

Precipitating Factors: Volume depletion, dehydration (tropical heat, gastroenteritis), sodium restriction, and concurrent administration of drugs that reduce renal lithium clearance: Thiazide Diuretics (induce proximal tubule sodium and lithium reabsorption), NSAIDs (inhibit renal prostaglandin synthesis, lowering GFR), and ACE Inhibitors / ARBs .

Clinical Manifestations:

Mild Toxicity (1.5 to 2.0 mmol/L): Coarse tremor, persistent nausea, vomiting, watery diarrhea, lethargy, muscle weakness.

Moderate to Severe Toxicity (> 2.0 to 2.5 mmol/L): Severe ataxia, dysarthria, nystagmus, myoclonic twitches, hyperreflexia, visual hallucinations, acute kidney injury, seizures, stupor, and coma.

Emergency Management: Discontinue lithium immediately. Administer aggressive intravenous hydration with 0.9% Normal Saline to restore intravascular volume and promote renal lithium clearance. Hemodialysis is recommended for reduced consciousness, seizures or life-threatening dysrhythmias regardless of lithium level , or impaired kidney function with lithium >4.0 mmol/L . EXTRIP also suggests it for lithium >5.0 mmol/L , significant confusion, or an expected time >36 hours to reach <1.0 mmol/L with optimal care. Seek urgent toxicology/nephrology advice and monitor serial levels for rebound.

Teratogenic Profile: Lithium exposure during the first trimester of pregnancy carries an increased risk of Ebstein's Anomaly (downward apical displacement of the tricuspid valve leaflets into the right ventricle, resulting in tricuspid regurgitation and severe atrialization of the right ventricle).

Teratogenicity of Anticonvulsant Mood Stabilizers

Valproate: Carries the highest teratogenic risk of all psychotropic medications, causing a 1% to 2% incidence of neural tube defects (spina bifida aperta, anencephaly) , facial clefts, and significant long-term neurodevelopmental delays (IQ deficits of 8-11 points). Valproate is strictly contraindicated in women of childbearing potential unless fully refractory to all other options and enrolled in a pregnancy prevention program with high-dose folate supplementation (5 mg daily).

Suicide Risk Assessment & Clinical Triage in Caribbean Practice

Suicide represents a profound, preventable tragedy. In several Caribbean territories—notably Guyana, Trinidad and Tobago, and rural agricultural belts in Jamaica—suicide rates are compounded by easy domestic access to lethal agricultural chemicals, particularly organophosphate insecticides and the bipyridyl herbicide paraquat (Gramoxone) . Registered medical practitioners must be adept in rapid risk stratification, lethal means restriction, and involuntary protective containment.

The Clinical Interview: Inquiring Directly

Evidence-Based Rule: Asking directly, clearly, and empathetically about suicidal thoughts does not plant ideas or increase the risk of suicide. On the contrary, it provides immediate psychological relief, validates emotional distress, and opens the door for lifesaving intervention.

Graded Exploration: Inquire systematically: (1) Passive thoughts of death ("Do you ever wish you would not wake up in the morning?"), (2) Active suicidal ideation ("Have you had thoughts of ending your life?"), (3) Plan ("Have you thought about how you might do it?"), (4) Intent ("Do you intend to act on these thoughts?"), and (5) Lethal Means Access ("Do you have access to medications, firearms, or agricultural chemicals at home?").

Static vs. Dynamic Suicide Risk Factors

Static (Unchangeable) Risk Factors: Male sex (higher completion rate, whereas females have higher attempt rates); age extremes (< 19 or > 45 years); prior suicide attempt (the single strongest clinical predictor of completed suicide) ; family history of suicide; chronic physical illness or severe intractable pain.

Dynamic (Modifiable) Clinical Factors: Active substance or alcohol intoxication; acute psychotic symptoms (command auditory hallucinations directing self-harm); severe psychic agitation or akathisia; global hopelessness; active domestic conflict or bereavement; immediate access to lethal means.

The SAD PERSONS Mnemonic: A historical checklist of risk factors; it must not determine admission or discharge:

  • S – Sex (Male = 1)
  • A – Age (< 19 or > 45 years = 1)
  • D – Depression or severe mood disorder (= 1)
  • P – Previous suicide attempt (= 1)
  • E – Ethanol or drug abuse (= 1)
  • R – Rational thinking loss (psychosis, severe depression = 1)
  • S – Social support lacking (= 1)
  • O – Organized plan with lethal intent (= 1)
  • N – No spouse (divorced, separated, widowed, single = 1)
  • S – Sickness (chronic, debilitating medical illness = 1)

Clinical Use: Do not use the score or a low/medium/high label to predict suicide or decide discharge. Formulate the person's immediate safety needs from current intent, plans, means, mental state, supports and ability to engage in care; arrange urgent specialist assessment when safety is uncertain.

Involuntary Admission & Regional Mental Health Legislation

Emergency psychiatric care follows the law of the jurisdiction , rather than a single regional detention rule. Maintain immediate observation and means restriction, seek urgent psychiatric assessment and offer voluntary care whenever feasible.

Compulsory Assessment/Admission : If voluntary care is refused and immediate safety cannot be maintained, assess the national statutory criteria, authorised applicant/certifier and least restrictive safe option. Document the grounds and the person's rights; mental illness alone does not remove decision-making capacity.

National Examples & Review : Jamaica's Mental Health Act provides ordinary and emergency application routes (sections 6 and 8), and examination within 72 hours after compulsory admission under section 6 (section 10). Guyana uses the Mental Health Protection and Promotion Act 2022 , in operation from 6 November 2023, with review/appeal safeguards. Use the applicable national forms and review limits; do not assume a universal physician-issued “72-hour hold”.

Lethal Means Restriction & Safety Planning: In outpatient practice, lethal means restriction is the single most effective public health suicide prevention strategy. Clinicians must actively collaborate with families to lock away agricultural pesticides, remove firearms, and dispense only limited 3- to 7-day supplies of medications that lack lethal cardiotoxicity in overdose (favoring SSRIs over TCAs).

Loading diagram... Suicide Risk Stratification & Clinical Intervention Algorithm